+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Adenosine 2A receptor is protective against renal injury in MRL/lpr mice.


      Adenosine, analogs & derivatives, pharmacology, Adenosine A2 Receptor Agonists, Animals, Blotting, Western, Disease Models, Animal, Disease Progression, Female, Gene Expression, Inflammation, drug therapy, physiopathology, Lupus Erythematosus, Systemic, genetics, Lupus Nephritis, Mice, Mice, Inbred MRL lpr, Phenethylamines, RNA, metabolism, Receptor, Adenosine A2A, Reverse Transcriptase Polymerase Chain Reaction

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Adenosine is considered as a potent endogenous anti-inflammatory and immunosuppressive molecule. We examined the roles of A2A-adenosine receptor (A(2A)R) in the progression of lupus nephritis. MRL/lpr mice were given a selective A(2A)R agonist, CGS21680 (0.4 mg/kg per day, i.p.) while control mice received saline only. After 8 weeks of treatment, mice were sacrificed for assessment of functional and histological parameters as well as inflammatory infiltration in the kidneys. MCP-1, IFN-γ, MHC-II and A(2A)R mRNA expression was evaluated by RT-PCR. Expression of A(2A)R and nuclear NFκB p65 protein was determined by Western blot analysis. Levels of anti-dsDNA antibody and IFN-γ were measured by ELISA. CGS21680 treatment resulted in significant decrease in proteinuria, blood urea and creatinine as well as improvement in renal histology. Renal macrophage and T-cell infiltration were significantly attenuated in association with suppressed expression of MCP-1, IFN-γ and MHC-II. CGS21680 treatment reduced the level of serum anti-dsDNA and renal immune complex deposition. CGS21680 inhibited the activation of NFκB and suppressed the expression of IFN-γ, MCP-1 and MHC-II in MRL/lpr splenocytes. A(2A)R activation suppressed inflammation in the kidneys of MRL/lpr mice and can be considered as a novel therapeutic approach for human lupus nephritis.

          Related collections

          Author and article information



          Comment on this article